Adding Zoldonrasib to Chemotherapy for Pancreatic Cancer Treatment
NCT07621718 · RecruitingThis study looks at how well a new medicine called zoldonrasib works when given with chemotherapy for people with a specific type of pancreatic cancer. The goal is to see if this combination helps patients live longer and have better outcomes compared to a placebo, which is a treatment that looks like the real medicine but has no active ingredients. The trial focuses on patients with metastatic KRAS G12D-mutated pancreatic adenocarcinoma who have not had treatment before.
Locations and contact
This trial is running at 3 locations in the United States. All of them are currently recruiting.
United States3 locations · 3 recruiting
- Johns Hopkins UniversityBaltimore, MarylandRecruiting
- Moffitt Cancer CenterTampa, FloridaRecruiting
- Piedmont HealthcareAtlanta, GeorgiaRecruiting
Who can join
Participants must be at least 18 years old and can be men or women. They need to have a confirmed diagnosis of pancreatic adenocarcinoma and a specific KRAS mutation. People who have had other cancer treatments before are not eligible to join. The trial team will confirm who can participate.
What happens during the trial
Participants will be randomly placed into one of two groups. One group will receive zoldonrasib along with a type of chemotherapy chosen by the doctor. The other group will receive a placebo with the same type of chemotherapy. All treatments are given as oral tablets or through IV infusions.
The trial team
The trial is sponsored by Revolution Medicines, Inc., which is responsible for the study.
Important dates
The trial started on May 22, 2026, and is expected to finish by April 22, 2030. It is currently recruiting new participants.
Additional information
The trial's ID number is NCT07621718. This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. It is regulated by the FDA and hopes to include about 670 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →